| Patient | Wilma Mankiller |
|---|---|
| Date of birth | 1991-11-18 |
| Identifiers | MRN HR-ML052-SYN; SSN (made up) 000-52-4183 |
| Document date | 2026-05-04 |
| Author | Rena Hawkfeather-Lindqvist, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review on pyridostigmine and prednisone. [S]
Ms. Mankiller returns six weeks after starting prednisone, which reached 40 mg each morning two weeks ago. She had no worsening as the dose rose. Her eyelids droop only late in the evening now, double vision is rare, and she can brush her hair and finish meals without resting. She sleeps less well and feels hungrier, and has gained about 2 kg. She has had no infections. The screening tests drawn at the last visit were normal: TPMT activity normal, hepatitis B surface antigen and core antibody negative with immunity from vaccination, and the tuberculosis blood test negative. She saw the thoracic surgeon two weeks ago, and a robotic thymectomy is planned in five weeks. Her home blood pressure readings average 118/76. She drinks about 2.5 liters of water a day. [S]
| Element | Detail |
|---|---|
| Prednisone | 40 mg each morning for two weeks; no early worsening |
| Strength | MG-ADL 3, from 7 |
| Screening | TPMT normal; hepatitis B and tuberculosis screens negative |
| Thymectomy | Robotic thymectomy planned in five weeks |
| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Mild ptosis late in the evening; double vision rare |
| Constitutional | Positive | Weight up about 2 kg; hungrier on prednisone |
| Psychiatric | Positive | Sleeps less well on prednisone; mood steady; PHQ-2 score 1 |
| Respiratory | Negative | No breathlessness; cough strong |
| Integumentary | Negative | No infections or skin problems |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eating | One tablet three times daily | Oral route | 2026-03-09 to 2026-03-23 | completed | S |
| Pyridostigmine bromide 60 mg oral tablet, one tablet four times daily while awake, 30 to 45 minutes before meals | One tablet four times daily while awake | Oral route | 2026-03-23 to 2026-10-12 | completed | S |
| Prednisone 10 mg oral tablet, 10 mg each morning, rising by 10 mg each week to 40 mg each morning, then held at 40 mg | Once each morning; dose as directed | Oral route | 2026-03-23 to 2026-07-13 | completed | S |
| Azathioprine 50 mg oral tablet, one tablet daily for two weeks, then two tablets daily, then three tablets (150 mg, about 2.3 mg/kg) daily | Once daily; dose as directed | Oral route | 2026-05-04 | active | S |
| Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet daily with food | One tablet daily with food | Oral route | 2026-03-23 | active | S |
| Cholecalciferol (vitamin D3) 1000 units (0.025 mg) oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Sulfamethoxazole 800 mg / trimethoprim 160 mg oral tablet, one tablet three times a week, while prednisone is 20 mg or more with azathioprine | One tablet on Monday, Wednesday and Friday | Oral route | 2026-05-04 to 2026-10-05 | completed | S |
| Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg pain | One or two tablets up to three times daily as needed | Oral route | 2025-09-15 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-04 | Body height | 163 | cm | S |
| 2026-05-04 | Body weight | 63.9 | kg | S |
| 2026-05-04 | Body mass index (BMI) [Ratio] | 24.1 | kg/m2 | S |
| 2026-05-04 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-05-04 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-05-04 | Heart rate | 80 | /min | S |
| 2026-05-04 | Respiratory rate | 16 | /min | S |
| 2026-05-04 | Body temperature | 36.6 | Cel | S |
| 2026-05-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-04 | Hemoglobin [Mass/volume] in Blood | 13.2 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-05-04 | Leukocytes [#/volume] in Blood by Automated count | 10.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-05-04 | Platelets [#/volume] in Blood by Automated count | 284 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-05-04 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-04 | Glucose [Mass/volume] in Serum or Plasma | 104 | mg/dL | 70-99 mg/dL | High | S |
| 2026-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 0.76 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 105 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 7-45 U/L | Normal | S |
| 2026-05-04 | Forced vital capacity [Volume] Respiratory system | 3.48 | L | Lower limit of normal about 2.9 L for her age, sex and height | Normal | S |
| 2026-05-04 | DXA Femur [Z-score] Bone density | -0.4 | {Z-score} | Above -2.0 is within the expected range for age | Normal | S |
| 2026-05-04 | DXA Lumbar spine [Z-score] Bone density | -0.7 | {Z-score} | Above -2.0 is within the expected range for age | Normal | S |
| 2026-05-04 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S |
Vital signs recorded on 2026-05-04; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 128/82 mm Hg; weight 63.9 kg |
| Eyes | No ptosis after one minute of upgaze; eye movements full |
| Neurological | Neck flexion 5 of 5; arm abduction held for 90 seconds; counts to 50 without a nasal voice |
| Respiratory | FVC 3.48 L |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Drooping eyelids and double vision for six weeks, worse in the evening, with fatigable weakness of the arms and neck, tiring when chewing and a nasal voice after long talks; a disorder of the neuromuscular junction suspected | resolved | confirmed | H53.2 | S — Synthetic presenting problem, resolved at the second visit when antibodies and nerve testing established myasthenia gravis. |
| Generalized myasthenia gravis, acetylcholine receptor antibody positive, MGFA class IIa, without thymoma; synthetic modern detail linked to her documented myasthenia gravis of 1980 | active | confirmed | G70.00 | S — Synthetic antibody level, electrodiagnosis, class and treatment; the diagnosis less than a year after the crash, and recovery with Cherokee medicine people, surgery and drug therapy, are documented (D). |
| Autosomal dominant polycystic kidney disease (hereditary, as she has described it), with normal kidney function; to be staged | active | confirmed | Q61.2 | S — The hereditary polycystic kidney disease is documented (D) from her later public account; its detection before the index date, and every value, are synthetic. |
| Recovery from major trauma in a head-on car crash last year: fractures of both legs, ribs and face, with many operations; walks independently, with a cane on rough ground | active | confirmed | Z87.81 | S — The crash, the operations and the injuries are documented (D); the current function is synthetic. |
| Long-term glucocorticoid therapy for myasthenia gravis, with monitoring of glucose, blood pressure, weight, bone health, mood, sleep, eyes and infection | active | confirmed | Z79.52 | S — Synthetic treatment plan. |
| Azathioprine as steroid-sparing therapy, with blood count and liver test monitoring | active | confirmed | Z79.624 | S — Synthetic treatment plan. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | MG-ADL score | Every visit | Completed today | 3, down from 7 |
| Imaging | Forced vital capacity | Every visit while on dose changes | Completed today | 3.48 L, up from 3.25 |
| Examination | Myasthenic crisis warning signs and early steroid worsening | Every visit | Completed today | None during the rise to 40 mg |
| Laboratory | Blood count before azathioprine | Baseline, then every one to two weeks for two months | Completed today | Hemoglobin 13.2 g/dL; white cells 10.4 on prednisone; platelets 284 |
| Laboratory | Chemistry: potassium, glucose, creatinine, eGFR and ALT | Baseline before azathioprine and periodically on glucocorticoids | Completed today | Potassium 4.0 mmol/L; glucose 104 mg/dL non-fasting; creatinine 0.76 mg/dL; eGFR 105; ALT 20 U/L |
| Laboratory | TPMT, hepatitis B and tuberculosis screening | Before azathioprine | Completed today | TPMT activity normal; hepatitis B surface antigen and core antibody negative, surface antibody positive; interferon-gamma release assay negative |
| Imaging | Bone density (DXA) | Soon after starting glucocorticoids expected to last more than three months | Completed today | Femoral neck Z-score -0.4; lumbar spine Z-score -0.7 |
| Examination | Blood pressure and weight | Every visit | Completed today | 128/82 mm Hg in clinic; home average 118/76; weight up 2.3 kg |
| Examination | Eye examination on glucocorticoids | Yearly | Due | Within the year, at the Cherokee Nation eye clinic |
| Medication safety | Pneumocystis prophylaxis | While prednisone is 20 mg or more with a second immunosuppressant | Completed today | Trimethoprim-sulfamethoxazole three times a week from today; potassium will be watched |
| Medication safety | Medicines that can worsen myasthenia gravis | With every new prescription | Completed today | Surgical and anesthesia teams told; the list sent with the thymectomy referral |
| Survey | Depression screen (PHQ-2) and sleep | At intervals | Completed today | PHQ-2 score 1; sleep shorter on prednisone |
| Referral | Thoracic surgery | Once | Completed today | Seen two weeks ago; robotic thymectomy planned in five weeks |
| Self-management | Home blood pressure and water intake | Every visit | Completed today | Home readings about 118/76; water about 2.5 liters a day |
Goal progress:
Guideline basis: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025); Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (2022)
Follow-up: Blood count and liver tests at two, four and six weeks at the Cherokee Nation clinic near her home. Thymectomy in five weeks. Review here five weeks after surgery. Next scheduled visit 2026-07-13: review five weeks after thymectomy: recovery, pathology, azathioprine monitoring, the prednisone taper, and kidney care. [S]